BRAF and neoplasm: More recently, the same authors published a multicentric study using the same method to analyze cfDNA from 66 advanced BRAF V600E/K melanoma patients treated with dabrafenib, in which BRAF mutation in pre-cfDNAs was associated significantly with tumor burden, PFS and OS (p < 0.05) [112].